title: Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization, natural biodistribution, and acute toxicity.
abstract: The clinical outcome of patients with ischemic heart disease can be significantly improved with the implementation of targeted drug delivery into the ischemic myocardium. In this paper, we present our original findings relevant to the problem of therapeutic heart targeting with use of nanoparticles. Experimental approaches included fabrication of carbon and silica nanoparticles, their characterization and surface modification. The acute hemodynamic effects of nanoparticle formulation as well as nanoparticle biodistribution were studied in male Wistar rats. Carbon and silica nanoparticles are nontoxic materials that can be used as carriers for heart-targeted drug delivery. Concepts of passive and active targeting can be applied to the development of targeted drug delivery to the ischemic myocardial cells. Provided that ischemic heart-targeted drug delivery can be proved to be safe and efficient, the results of this research may contribute to the development of new technologies in the pharmaceutical industry.
authors.affiliation: Institute of Experimental Medicine, VA. Almazov Federal Heart, Blood and Endocrinology Center, St-Petersburg, Russian Federation. galagoudza@mail.ru
authors.forename: Michael M
authors.initials: MM
authors.lastname: Galagudza
authors.forename: Dmitry V
authors.initials: DV
authors.lastname: Korolev
authors.forename: Dmitry L
authors.initials: DL
authors.lastname: Sonin
authors.forename: Viktor N
authors.initials: VN
authors.lastname: Postnov
authors.forename: Garry V
authors.initials: GV
authors.lastname: Papayan
authors.forename: Ivan S
authors.initials: IS
authors.lastname: Uskov
authors.forename: Anastasia V
authors.initials: AV
authors.lastname: Belozertseva
authors.forename: Eugene V
authors.initials: EV
authors.lastname: Shlyakhto
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D004337:Drug Carriers / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000493:pharmacokinetics; D008297:Male; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000378:metabolism*; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D009928:Organ Specificity; D051381:Rats; D017208:Rats, Wistar; D012822:Silicon Dioxide / Q000737:chemistry*; D014018:Tissue Distribution; D016896:Treatment Outcome
chemical_list: D002316:Cardiotonic Agents; D004337:Drug Carriers; D012822:Silicon Dioxide
references.citation: ACS Nano. 2009 Oct 27;3(10):3273-86
references.pmid: 19739605
references.citation: Prog Lipid Res. 2005 Jul;44(4):207-34
references.pmid: 15979148
references.citation: Adv Drug Deliv Rev. 2008 Aug 17;60(11):1278-88
references.pmid: 18514969
references.citation: J Am Chem Soc. 2009 Jun 24;131(24):8398-400
references.pmid: 19476380
references.citation: Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
references.pmid: 2946403
references.citation: Chem Commun (Camb). 2009 Jun 14;(22):3219-21
references.pmid: 19587919
references.citation: J Am Coll Cardiol. 2009 Feb 24;53(8):709-17
references.pmid: 19232905
references.citation: Cardiovasc Hematol Disord Drug Targets. 2009 Sep;9(3):206-21
references.pmid: 19817715
references.citation: Nano Lett. 2009 Sep;9(9):3308-11
references.pmid: 19736973